Anika Therapeutics (ANIK) Income from Continuing Operations (2010 - 2026)
Anika Therapeutics (ANIK) reported Income from Continuing Operations of 5056000.0 for Q1 2026, down 27.39% year-over-year from 6962964.61 in Q1 2025, and down 142.0% quarter-over-quarter from 12039000.0 in Q4 2025.
Anika Therapeutics (ANIK) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 17 years of Income from Continuing Operations data on file, last reported at 5056000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 5056000.0, down 27.39% year-over-year; the trailing twelve-month figure through Mar 2026 was 839000.0 (up 93.11% YoY), and the FY2025 annual result was 268000.0, up 102.64% from the prior year.
- Income from Continuing Operations fell to 5056000.0 in Q1 2026 per ANIK's latest filing, from 12039000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 17100000.0 in Q4 2023 and troughed at 10350000.0 in Q1 2023.
- A 5-year average of 1258647.06 and a median of 2933000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations sank 845.88% in 2022, then surged 416.82% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 6080000.0 in 2022, then jumped by 181.25% to 17100000.0 in 2023, then sank by 122.22% to 3800000.0 in 2024, then surged by 416.82% to 12039000.0 in 2025, then tumbled by 142.0% to 5056000.0 in 2026.
- Business Quant data shows ANIK's Income from Continuing Operations at 5056000.0 in Q1 2026, 12039000.0 in Q4 2025, and 3175000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn | -5.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.06 Mn |
| Dec 31, 2025 | 12.04 Mn |
| Sep 30, 2025 | -3.18 Mn |
| Jun 30, 2025 | -4.65 Mn |
| Mar 31, 2025 | -3.97 Mn |
| Dec 31, 2024 | -3.80 Mn |
| Sep 30, 2024 | -1.88 Mn |
| Jun 30, 2024 | -2.54 Mn |
| Mar 31, 2024 | -1.96 Mn |
| Dec 31, 2023 | 17.10 Mn |
| Sep 30, 2023 | -6.54 Mn |
| Jun 30, 2023 | -2.77 Mn |
| Mar 31, 2023 | -10.35 Mn |
| Dec 31, 2022 | 6.08 Mn |
| Sep 30, 2022 | -4.16 Mn |
| Jun 30, 2022 | -2.84 Mn |
| Mar 31, 2022 | -2.93 Mn |
| Dec 31, 2021 | -10.75 Mn |
| Sep 30, 2021 | 558,000.00 |
| Jun 30, 2021 | 6.53 Mn |